Zinc supplementation to improve prognosis in patients with compensated advanced chronic liver disease

Zinc homeostasis could play a role in compensated advanced chronic liver disease, and its supplementation has been linked to improvement in liver function, a decrease of hepatic complications, and reduction in HCC incidence. Compensated advanced chronic liver disease encompasses a heterogeneous grou...

Full description

Bibliographic Details
Authors: Bañares, Juan|||0000-0002-1966-1947, Aceituno, Laia|||0000-0001-5414-2408, Ruiz-Ortega, Lourdes|||0000-0003-3636-3367, Pons Delgado, Mònica|||0000-0002-0985-3320, Abraldes, Juan G.|||0000-0003-3421-937X, Genescà Ferrer, Joan|||0000-0002-0831-8422
Format: article
Publication Date:2024
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:322328
Online Access:https://ddd.uab.cat/record/322328
https://dx.doi.org/urn:doi:10.1097/HC9.0000000000000524
Access Level:Open access
Keyword:Cirrhosis
First decompensation
Hepatocellular carcinoma
Portal hypertension
Zinc
Description
Summary:Zinc homeostasis could play a role in compensated advanced chronic liver disease, and its supplementation has been linked to improvement in liver function, a decrease of hepatic complications, and reduction in HCC incidence. Compensated advanced chronic liver disease encompasses a heterogeneous group of patients with variable risks of clinically significant portal hypertension and clinical events. The ANTICIPATE model is a validated model for stratifying these risks. Our aim is to demonstrate that zinc administration can reduce the rate and risk of presenting clinical events (first decompensation, HCC, death, and liver transplantation). This study protocol describes an ongoing phase III, national, multicenter, randomized, double-blind clinical trial that will enroll 300 patients to receive either the trial treatment (zinc acexamate) or placebo. An inclusion period of 42 months is planned, with a minimum follow-up of 2 years. Our principal hypothesis is that zinc could modify the natural history of patients with compensated advanced chronic liver disease, with an overall improvement in prognosis.